Pavia, l'oncologia della Maugeri al top - Cronaca - ilgiorno.it
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all? - Porta - Annals of Translational Medicine
Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data - Mimma Rizzo, Matteo Santoni, Camillo Porta, 2020
Terapie di combinazione: il punto su melanoma, carcinoma polmonare e carcinoma renale - OncoInfo
T:: l pbnoio tor8
Renal cell carcinoma treatment after first-line combinations - The Lancet Oncology
PDF) Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma
Mirrors of Medicine - PinPoint cases - Esperti e collaboratori
COVID-19: il ruolo degli oncologi - OncoInfo
Carcinoma renale avanzato: una terapia innovativa in prima linea - OncoInfo
Axitinib Did Not Meet Study End Point in mRCC, but Dosing Found Feasible - Cancer Therapy Advisor
Camillio PORTA | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO) | Research profile
2018 Impact Factor 17.298
Frontiers | Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma
Edgar V. Lerma 🇵🇭 on Twitter: "Renal Cell Carcinoma Staging #Nephpearls https://t.co/3D5YaTBnlJ" / Twitter
April 2020 Reviewer of the Month - Reviewer Name: European Urology
Numero 3, Luglio-Settembre - Azienda ospedaliera S.Camillo ...
Immune-based combination therapy for metastatic kidney cancer | Nature Reviews Nephrology
WHICH IMMUNOTHERAPY IS THE STANDARD 1ST LINE THERAPY IN mRCC – IMMUNE COMBOS WITH A TKI
maugeri - insalutenews.it
The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review - ScienceDirect
Nicole Gri (@NikGri93) / Twitter
JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study
